Changzhou Qianhong Biopharma: Changzhou Qianhong Biopharma: Performance Forecast for the First Half of 2024.
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?
Changzhou Qianhong BiopharmaLTD's (SZSE:002550) stock is up by 9.8% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, w
Income Investors Should Know That Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Goes Ex-Dividend Soon
Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) is about to trade ex-dividend in the next two days. The ex-dividend date is one business day before the record date, which is the cut-off date for s
Investors Appear Satisfied With Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Prospects As Shares Rocket 26%
Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) shares have had a really impressive month, gaining 26% after a shaky period beforehand. Longer-term shareholders would be thankful for the recover
Qianhong Pharmaceutical (002550.SZ) 2023 equity distribution: 1.2 yuan for every 10 shares
Qianhong Pharmaceutical (002550.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...
Qianhong Pharmaceutical (002550.SZ): The holding subsidiary Zhonghong Research Institute has laid out synthetic biology techniques such as genetic engineering and biological extraction
Gelonghui May 9丨Qianhong Pharmaceutical (002550.SZ) held a performance briefing on May 9, 2024 to discuss “Is the company involved in synthetic biotechnology?” The company replied that Zhonghong Research Institute, a holding subsidiary of the company, has laid out synthetic biology techniques such as genetic engineering and biological extraction to develop innovative macromolecular drugs. Related products are still in the development process and have not entered the industrialization stage.
Qianhong Pharmaceutical (002550.SZ): The new drug is mainly used in the treatment of diseases such as tumors, cardiovascular and cerebrovascular diseases
Gelonghui May 9丨Qianhong Pharmaceutical (002550.SZ) held a performance briefing on May 9, 2024 to discuss “What drug types or treatment fields is the company's R&D investment mainly focused on? What is the market potential in these areas?” The company replied that the company's new drugs are mainly used in the treatment of diseases such as tumors, cardiovascular and cerebrovascular diseases, and they all have broad market prospects.
Qianhong Pharmaceutical (002550.SZ): The Qianmu project is scheduled to be put into production by the end of 2024
Gelonghui May 9丨Qianhong Pharmaceutical (002550.SZ) held a performance briefing on May 9, 2024, to discuss “When will the Hubei Zhongxiang factory and Qianmu factory be able to start production this year? Can you tell me about the progress and effects of the new drug?” The company replied that the Qianmu project is scheduled to be put into production by the end of 2024 and is expected to contribute to performance in 2025. The Hubei project is under construction. A number of new drugs are undergoing clinical trials and are currently progressing well.
Qianhong Pharmaceutical (002550.SZ): QHRD107, the fastest progressing new drug project at present (indicated for recurrent intractable acute myeloid leukemia), is expected to make phased progress by the end of the year
Gelonghui May 9丨Qianhong Pharmaceutical (002550.SZ) held a performance briefing on May 9, 2024. Regarding “The company mentioned that innovative drugs have entered or are about to enter phase II clinical trials, can you give a detailed introduction to the development progress, market potential, and expected launch time of these new drugs? What strategic significance does the development of these new drugs have for the future development of the company?” The company replied that the company's fastest progressing new drug project, QHRD107 (indicated for recurrent acute myeloid leukemia), is a CDK9 kinase inhibitor type small molecule class 1 new drug. It has completed phase IIa clinical climb
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Shareholder Returns Have Been Decent, Earning 31% in 3 Years
By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, Changzhou Qianhong Biopharma
Qianhong Pharmaceutical (002550.SZ): Net profit of 104 million yuan in the first quarter increased 21.13% year over year
On April 25, Ge Longhui Pharmaceutical (002550.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 461 million yuan, down 24.19% year on year; net profit attributable to shareholders of listed companies was 104 million yuan, up 21.13% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 102 million yuan, up 19.11% year on year; basic earnings per share were 0.0827 yuan.
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Could Easily Take On More Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Qianhong Pharmaceutical (002550.SZ): The repurchase was completed with a cumulative cost of 141 million yuan to repurchase 1.95% of the shares
Gelonghui, March 22 | Qianhong Pharmaceutical (002550.SZ) announced that as of March 22, 2024, the repurchase plan has been implemented. In this repurchase plan, the company has repurchased 25,000,000 shares through a dedicated securities account, accounting for 1.95% of the company's current total share capital. The maximum transaction price is 6.06 yuan/share, and the minimum transaction price is 4.47 yuan/share. The total repurchase amount paid is 141 million yuan (excluding transaction fees).
Qianhong Pharmaceutical (002550.SZ): 1.95% of shares have been repurchased
Gelonghui, March 1 | Qianhong Pharmaceutical (002550.SZ) announced that as of February 29, 2024, the company had repurchased 25,000,000 shares through centralized bidding transactions through a special repurchase account, accounting for 1.95% of the company's total share capital. The highest transaction price for the repurchase was 6.06 yuan/share, the minimum transaction price was 4.47 yuan/share, and the total amount paid was 140,756,897 yuan (not including transaction fees).
Qianhong Pharmaceutical (002550.SZ): A total cost of 132 million yuan to buy back 1.81% of the shares
Gelonghui, Feb. 2 | Qianhong Pharmaceutical (002550.SZ) announced that as of January 31, 2024, the company had repurchased 23,160,000 shares through centralized bidding transactions through the repurchase of special securities accounts, accounting for 1.81% of the company's total share capital. The highest transaction price for the repurchase was 6.06 yuan/share, the minimum transaction price was 4.89 yuan/share, and the total amount paid was 132 million yuan (excluding transaction fees).
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Sheds 8.8% This Week, as Yearly Returns Fall More in Line With Earnings Growth
When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make significant gains if you buy good quality businesses at the right price. To wit,
Qianhong Pharmaceutical (002550.SZ): A total of 1.10% of the shares have been repurchased in this repurchase
Gelonghui, January 16 | Qianhong Pharmaceutical (002550.SZ) announced that as of January 16, 2024, the company had repurchased 14,075,000 shares through centralized bidding transactions through the repurchase of special securities accounts, accounting for 1.10% of the company's total share capital. The maximum transaction price for the repurchase was 6.06 yuan/share, and the minimum transaction price was 5.67 yuan/share. The total amount paid was 8306.4738 million yuan (excluding transaction fees).
Qianhong Pharmaceutical (002550.SZ): Initial repurchase of 6.655 million shares involving 394.019 million yuan
Gelonghui, January 5 | Qianhong Pharmaceutical (002550.SZ) announced that on January 5, 2024, for the first time, the company repurchased 6.655 million shares of the company's shares through a special stock repurchase securities account, accounting for 0.51% of the company's current total share capital. The highest transaction price was 6.06 yuan/share, the lowest transaction price was 5.87 yuan/share, and the total transaction amount was 394.0.1.91 million yuan (excluding transaction fees).
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
Changzhou Qianhong BiopharmaLTD's (SZSE:002550) stock is up by a considerable 23% over the past three months. However, in this article, we decided to focus on its weak fundamentals, as long-term fin
Qianhong Pharmaceutical (002550.SZ): The Qianmu project has recently started construction and is scheduled to be tested in 2024
Gelonghui November 30 | Qianhong Pharmaceutical (002550.SZ) said on an interactive platform on November 30 that the company's Qianmu project has recently started construction. The project is expected to last 1 year, trial production is planned in 2024, and is expected to contribute to performance in 2025.
No Data